Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Non Operating Investment Income of -$100000.0 for Q1 2026, down 566.67% year-over-year from $21428.6 in Q1 2025, and down 766.67% quarter-over-quarter from $15000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Non Operating Investment Income for 5 consecutive years, with -$100000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 566.67% year-over-year to -$100000.0; the TTM figure through Mar 2026 stood at -$77000.0 (down 134.84% YoY), while the FY2025 annual figure was $8000.0, down 87.1% from the prior year.
- Non Operating Investment Income fell to -$100000.0 in Q1 2026 per OBIO's latest filing, from $15000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.7 million in Q2 2022 and bottomed at -$1.2 million in Q4 2022.
- Historically, Non Operating Investment Income has averaged $7058.8 across 5 years, with a median of -$15000.0 in 2024.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income soared 536.84% — and 2025, when it slumped 850.0%.
- Orchestra BioMed Holdings' Non Operating Investment Income stood at -$1.2 million in 2022, then soared by 104.24% to $51000.0 in 2023, then surged by 154.9% to $130000.0 in 2024, then sank by 88.46% to $15000.0 in 2025, then slumped by 766.67% to -$100000.0 in 2026.
- Business Quant data shows OBIO's Non Operating Investment Income at -$100000.0 in Q1 2026, $15000.0 in Q4 2025, and $29000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -41,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Sep 30, 2023 | 293,000.00 |
| Jun 30, 2023 | -61,000.00 |
| Mar 31, 2023 | -27,000.00 |
| Dec 31, 2022 | -165,000.00 |
| Sep 30, 2022 | -314,000.00 |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | -220,000.00 |